Policy in focus: Is psilocybin the next cannabis?
Canadian Medical Association Journal – November 14, 2021
Source: OpenAlex
Summary
A single psilocybin dose helped 60% of participants overcome long-term addiction in a recent trial, marking a profound shift for psychiatry. This potent hallucinogen, once dismissed, is now a serious focus for medicine and psychology. Paralleling the "wild west" of Cannabis dispensaries, the burgeoning field of Psychedelics and Drug Studies, including Cannabis and Cannabinoid Research, compels political science to re-examine drug policy. This resurgence demands a new, almost MAGIC-like focus to fully understand their therapeutic potential.
Abstract
Research interest in the therapeutic use of psilocybin, or "magic mushrooms," is growing alongside a "wild west" of dispensaries in Canada and the United States. The past decade has seen a revival of research exploring the clinical use of psychedelics in treating depression, addiction,